Actively Recruiting
Long-Term Assessment of the Altaviva Tibial Neuromodulation Device for Urge Urinary Incontinence Treatment
Led by MedtronicNeuro · Updated on 2026-10-20
256
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the long-term safety and effectiveness of the Altaviva system, a programmable neurostimulation device used to treat Urge Urinary Incontinence UUI. This prospective, multicenter study focuses on understanding how well this device performs over time in patients diagnosed with UUI. The study is sponsored by MedtronicNeuro and aims to assess outcomes up to 60 months after treatment. Participants in this study will receive treatment with the Altaviva system, which delivers electrical stimulation to the tibial nerve to provide tibial neuromodulation therapy. The study involves a single group of participants and does not use masking or randomization. The treatment and follow-up will continue for an extended period, with the primary endpoint measured at 60 months to evaluate durability and sustained effectiveness. During the study, participants will be asked to complete study questionnaires, attend scheduled visits, and operate the Altaviva system as directed. Researchers will assess safety and treatment outcomes through a variety of measures, including a 3-day voiding diary, to track urinary urge incontinence episodes. Patients will be monitored closely to ensure adherence and study protocol compliance throughout the long-term follow-up period, which lasts until November 2032.
CONDITIONS
Brief Title
Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device
Research Team
M
Mylene Champs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here